We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Protein Fragment Promotes Anti-Cancer Response

By LabMedica International staff writers
Posted on 22 May 2017
Print article
Image: When free C3d vaccine was added to a tumor, the cancer cells began to die (right). Tumor cells not given the vaccine continued to grow (Photo courtesy of the University of Michigan).
Image: When free C3d vaccine was added to a tumor, the cancer cells began to die (right). Tumor cells not given the vaccine continued to grow (Photo courtesy of the University of Michigan).
Free C3d protein, a fragment of the third component of complement, has been found to prevent cancer cells from avoiding the body's immune response and has potential to be developed into a chemotherapeutic agent for cancer treatment.

Tumors escape the immune system by engaging T- cell checkpoint regulators and expanding regulatory T-cells (Tregs), among other mechanisms. The molecular factors that control these mechanisms are unknown.

Investigators at the University of Michigan reported in the May 4, 2017, online edition of the Journal of Clinical Investigation Insight that free C3d - inside tumor cells or associated with irradiated tumor cells and unattached to antigen - recruited, accelerated, and amplified antitumor T-cell responses, allowing the immune system to reverse or even to prevent tumor growth. These findings were obtained from studies on mice melanoma and lymphoma models.

C3d enhanced antitumor immunity independently of B-cells, NK cells, or antibodies, but it did so by increasing tumor infiltrating CD8+ lymphocytes, by depleting Tregs, and by suppressing expression of programmed cell death protein 1 (PD-1) by T-cells. These properties of C3d appeared to be specific for the tumor and dependent on complement receptor II, and they incurred no obvious systemic toxicity.

"Our cancer therapy blocks tumor-induced immunosuppression. Because it is natural, it does not have adverse effects as far as we know," said senior author Dr. Marilia Cascalho, associate professor of surgery, microbiology, and immunology at the University of Michigan. "The most recent success in cancer immunotherapy is with agents that block the inhibition of the immune system. Even though there has been success with immunotherapy, the problem is that immunotherapy is not specific. The drugs work everywhere, so there are many secondary effects. Our cancer therapy takes an entirely new path to blocking tumor-induced immunosuppression. It is different because when free C3d was injected into cancer cells in the research, it did not appear to have side effects."

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.